Healthcare · Profile from Healthcare Research Companion
mPharma
The Accra-founded company that set out to fix Africa's broken medicine supply chain from the pharmacy counter backwards. It started by managing inventory for independent pharmacies and hospitals, then bought pharmacy chains in Kenya, Uganda and Nigeria, built its own "mutti" pharmacy brand, franchise programme (QualityRx), patient membership and in-pharmacy telemedicine (Mutti Doctor), and raised roughly $80–90m from Silicon Valley, development-finance and pharma investors (reported). Currency collapses in Ghana and Nigeria in 2022–2024 forced layoffs and a narrower footprint, and in September 2025 co-founder Gregory Rockson handed the CEO role to Kwesi Arhin.
At a glance
- Founded
- June 2013, Accra, Ghana (reported)
- Founders
- Gregory Rockson (CEO 2013–2025, then chairman), Daniel Shoukimas and James Finucane (a US technologist)
- Headquarters
- Accra, Ghana; operating subsidiaries in other African markets
- Ownership / structure
- Private, venture-backed. Holding company with country subsidiaries (e.g. mPharma Ghana Ltd); majority stakes in acquired chains (Haltons, Kenya, ~85% reported; Vine Pharmacy, Uganda, 55%; HealthPlus, Nigeria, majority, undisclosed)
- Leadership (2026)
- Kwesi Arhin, FCCA, CEO from September 2025 (joined April 2023 as SVP; COO from July 2025); Gregory Rockson, co-founder and board chair (verify other executives)
- Segment and buyer
- Pharmacy supply chain, retail pharmacy and primary-care services in sub-Saharan Africa. Buyers: independent pharmacies and hospitals (inventory and supply), patients paying cash at mutti pharmacies, governments (Gabon supply-chain contract), and pharmaceutical manufacturers (distribution and patient programmes)
- Scale
- ~70 pharmacies in the network (late 2017, reported); ~200 facilities (January 2022, reported); "over 500 pharmacies across nine countries" (company, March 2024, reported); Mutti membership from fewer than 10,000 (2019) to 400,000+ (end-2024, company); "over 200,000 monthly patients" (September 2023, company). Revenue and profitability are not disclosed
- Capital raised / valuation
- ~$5m seed (2016, reported), $6.6m Series A (2017), ~$9.7m Series B (2019), $17m Series C (2020, led by CDC Group), $35m Series D (January 2022, $30m equity plus $5m Citi debt), $13.6m (January 2024, Sanofi Global Health Unit Impact Fund named), undisclosed GIP Ghana investment (November 2025). Total ~$80–90m (aggregators vary). No valuation disclosed
- Signature moves (incl. failures)
- Vendor-managed inventory for independent pharmacies (2013); Silicon Valley-backed Series A (2017); Haltons acquisition in Kenya (2019); Mutti membership and QualityRx franchise (2019 onward); Series C and COVID diagnostics infrastructure (2020); Ethiopia, Gabon and Uganda expansion (2021); Series D and Mutti Doctor telemedicine (2022); contested HealthPlus deal in Nigeria (2022); 150 layoffs after the naira and cedi shocks (2023); founder-to-operator CEO succession and GIP investment (2025)
10 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
2013
Founding and Vendor Managed Inventory
Founding / launch
2017
Series A and Silicon Valley Backers
Funding round
2019
Haltons Kenya Acquisition
Acquisition
2019
Mutti Membership and QualityRx Franchise
Launch / business model (consumer membership plus pharmacy franchise)
2020
Series C and Covid Diagnostics
Funding round / launch (diagnostics and pandemic response)
2021
Ethiopia Uganda Gabon Expansion
Expansion / franchise partnership / acquisition / government contract
2022
HealthPlus Nigeria Acquisition
Acquisition (majority stake)
2022
Series D and Mutti Doctor
Funding round / launch (in-pharmacy telemedicine)
2023
Layoffs and Currency Shock
Restructuring (layoffs, refocus) followed by a smaller funding round
2025
CEO Succession and GIP Investment
Leadership change / strategic investment